UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Feb

    27

    On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

    Read More Share:linkedin| twitter| email| facebook

    Feb

    26

    Beyond the Diagnosis: Embracing the Humanity Behind Epilepsy Care

    Read More Share:linkedin| twitter| email| facebook

    Feb

    25

    Shining a Light on Resilience: Honoring Black History Month and Raising Awareness for Epilepsy

    Read More Share:linkedin| twitter| email| facebook

    Feb

    12

    Providing U.S. Policy Actions on Rare Disease

    Read More Share:linkedin| twitter| email| facebook

    Feb

    03

    Rare Disease Day 2025: Elevating the Lives of the Under-served and Under-represented

    Read More Share:linkedin| twitter| email| facebook

    Jan

    31

    Voices on Value: Supporting People Impacted by Rare Disease through an Effective Policy Landscape

    Read More Share:linkedin| twitter| email| facebook

    Jan

    16

    UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

    Read More Share:linkedin| twitter| email| facebook

    Dec

    18

    Charting the Future: UCB’s 2024 Achievements are Fueling our 2025 Ambitions

    Read More Share:linkedin| twitter| email| facebook

    Dec

    06

    UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting

    Read More Share:linkedin| twitter| email| facebook

    Nov

    26

    UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting

    Read More Share:linkedin| twitter| email| facebook

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)